Abstract Purpose of Review Urothelial carcinoma (UC) is a common malignancy with an
urgent need for more effective and less toxic treatment strategies. Antibody-drug conjugate …

Metastatic urothelial carcinoma (UC) carries a poor prognosis and a 5-year overall survival
of less than 5%, despite standard of care therapy using cisplatin-based chemotherapy and …

Introduction The therapeutic landscape for urothelial carcinoma has changed significantly
over the past few years with the addition of immunotherapy to platinum-based …

Antibody–drug conjugates (ADCs) have transformed the treatment landscape in oncology
and become an essential therapeutic modality. In urothelial carcinoma (UC), the two ADCs …

The standard of care for advanced urothelial carcinoma includes platinum chemotherapy
and immunotherapy. Antibody-drug conjugates (ADCs), originally developed for …

In recent years, considerable progress has been made in increasing the knowledge of
tumour biology and drug resistance mechanisms in urothelial cancer. Therapeutic strategies …

Opinion Statement Over the last several years, the treatment landscape of urothelial
carcinoma has witnessed an unprecedented expansion of therapeutic options including …

Antibody-drug conjugates (ADCs) have joined the armamentarium against urothelial cancer
(UC) as an effective therapy option. Since 2019, the US Food and Drug Administration has …

Urothelial carcinoma (UC) is characterized by expression of a plethora of cell surface
antigens, thus offering opportunities for specific therapeutic targeting with use of antibody …

In the past, there was no second-line chemotherapeutic agent suitable for use when
urothelial carcinoma (UC) progressed to platinum-resistant UC. However, recently, several …